How India Exports Vancomycin to the World

In the United States, vancomycin is approved for various formulations, including intravenous and oral solutions. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for vancomycin, indicating a competitive generic market. Notably, on November 14, 2022, the FDA approved Alkem Laboratories Ltd.'s generic version of Firvanq, an oral vancomycin hydrochloride solution, in strengths of 25 mg/mL and 50 mg/mL. This approval underscores the FDA's commitment to expanding access to essential antibiotics.

Given the substantial number of Indian exporters (318) supplying vancomycin to the U.S., adherence to FDA regulations is paramount. Compliance with Current Good Manufacturing Practices (cGMP) and successful ANDA approvals are essential for market entry. Import alerts, which can arise from non-compliance, may significantly impact market access and should be diligently monitored.

In the European Union, vancomycin is subject to the European Medicines Agency's (EMA) regulatory oversight. Marketing authorization requires compliance with the EMA's stringent guidelines, including adherence to Good Manufacturing Practice (GMP) standards. The EMA conducts periodic safety update report single assessments (PSUSAs) for vancomycin to ensure ongoing pharmacovigilance. For instance, in December 2025, the EMA published a PSUSA for vancomycin, resulting in variations to the product information to enhance safety measures. (ema.europa.eu)

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and monitoring of medicinal products. Post-Brexit, the UK has established its own regulatory framework, necessitating separate marketing authorizations for vancomycin. Compliance with UK-specific GMP requirements and pharmacovigilance obligations is essential for market access.

Vancomycin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in treating severe bacterial infections. The 23rd edition of the list, updated in July 2023, continues to feature vancomycin, reflecting its enduring importance in global health. (test-cms.who.int) Additionally, vancomycin formulations are subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy across markets.

In India, vancomycin is classified as a Schedule H drug under the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The Central Drugs Standard Control Organization (CDSCO) mandates that manufacturers obtain a No Objection Certificate (NOC) for the export of vancomycin formulations. Additionally, the National Pharmaceutical Pricing Authority (NPPA) regulates the ceiling price of vancomycin to ensure affordability; the latest revision was implemented in March 2025.

Vancomycin's primary patents have long expired, facilitating a robust generic market. However, secondary patents related to specific formulations or delivery methods may still be in effect. For example, in April 2025, a U.S. court ruled that Azurity Pharmaceuticals could not enforce its patent on a vancomycin liquid formulation against Alkem Laboratories Ltd., highlighting the complexities of patent litigation in the pharmaceutical sector.

In December 2025, the EMA published a periodic safety update report single assessment (PSUSA) for vancomycin, leading to variations in product information to enhance safety measures. (ema.europa.eu)

In April 2025, a U.S. court ruled that Azurity Pharmaceuticals could not enforce its patent on a vancomycin liquid formulation against Alkem Laboratories Ltd., impacting the competitive landscape for vancomycin products.

In November 2022, the FDA approved Alkem Laboratories Ltd.'s generic version of Firvanq, an oral vancomycin hydrochloride solution, expanding treatment options for Clostridioides difficile infections.

In March 2025, the NPPA revised the ceiling price for vancomycin in India, reflecting efforts to balance affordability with industry sustainability.

In July 2023, the WHO updated its Model List of Essential Medicines, reaffirming vancomycin's status as a critical antibiotic for severe infections. (test-cms.who.int)

These developments underscore the dynamic regulatory and market environment surrounding vancomycin, necessitating continuous monitoring and compliance to ensure successful market participation.

India's pharmaceutical industry, including the production of Vancomycin, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in the API sector. This dependency poses significant risks, as disruptions in Chinese supply chains can directly impact Indian pharmaceutical manufacturing.

In recent years, environmental regulations in China have led to the shutdown of numerous API manufacturers, causing supply disruptions and cost escalations. For instance, over the last year, nearly 1.5 lakh factories in China have closed down, of which a quarter will affect pharmaceuticals. Such events underscore the vulnerability of India's pharmaceutical supply chain due to its reliance on Chinese KSMs.

Our proprietary trade data indicates that the top five Indian exporters account for 67.1% of Vancomycin exports, with MYLAN LABORATORIES LIMITED alone contributing 28.2% ($26.0M). This high supplier concentration increases the risk of supply chain disruptions, as issues affecting these key players can have a disproportionate impact on global Vancomycin availability.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic API production and reduce import dependence. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and 6-APA, essential for antibiotics production. While these initiatives are steps toward self-reliance, their impact on reducing supplier concentration in the Vancomycin supply chain remains to be seen.

Geopolitical tensions and shipping disruptions pose additional risks to the Vancomycin supply chain. The Red Sea and Strait of Hormuz are critical maritime routes for pharmaceutical exports; any instability in these regions can lead to delays and increased shipping costs. Furthermore, escalating US-China tensions have heightened concerns over the security of API supplies, given China's significant role in the global pharmaceutical industry.

Regulatory bodies have been monitoring these developments closely. The European Medicines Agency (EMA) reported in February 2026 that, since 2022, they have been monitoring the supply of a subset of antibiotics commonly used to treat respiratory infections. In 2025, the supply situation was more stable than in previous years, with additional supply sources contributing to improved availability. (ema.europa.eu) This indicates a proactive approach to managing potential shortages arising from geopolitical and logistical challenges.

• Diversify API and KSM Sources: Reduce reliance on Chinese imports by developing alternative suppliers in other regions, such as Eastern Europe and Mexico, to enhance supply chain resilience.

• Strengthen Domestic Production: Accelerate the implementation of the PLI scheme and similar initiatives to boost local manufacturing of critical APIs and KSMs, thereby decreasing import dependence.

• Enhance Supplier Due Diligence: Conduct comprehensive assessments of key suppliers to identify potential risks and develop contingency plans for supply disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on the pharmaceutical supply chain, enabling timely responses to emerging threats.

• Invest in Supply Chain Transparency: Implement advanced tracking systems to gain real-time visibility into the supply chain, facilitating prompt identification and mitigation of disruptions.

RISK_LEVEL: HIGH